Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma

Journal of Clinical Oncology

Volumn 16, Issue 6, 1998, Pages 2169-2180

  Yu, Alice L ^a   Uttenreuther Fischer, Martina M ^a   Huang, Chiun Sheng ^a   Tsui, Cynthia C ^a   Gillies, Steven D ^a   Reisfeld, Ralph A ^a   Kung, Faith H ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GANGLIOSIDE; MONOCLONAL ANTIBODY CH14 18; UNCLASSIFIED DRUG;

ARTICLE; CHIMERA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; FEVER; HUMAN; HYPERTENSION; IMMUNOGENICITY; NEUROBLASTOMA; OSTEOSARCOMA; PAIN; PHASE 1 CLINICAL TRIAL; PREVALENCE; PRIORITY JOURNAL; TACHYCARDIA; TARGET CELL; URTICARIA;

EID: 0031750167     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.6.2169     Document Type: Article

References (52)

1. Young JLJ, Miller RW: Incidence of malignant tumors in US children. J Pediatr 86:254-258, 1975
2. Evans AE, D'Angio GJ, Koop CE: Diagnosis and treatment of neuroblastoma. Pediatr Clin North Am 23:161-170, 1976
3. Shafford EA, Rogers DW, Pritchard J: Advanced neuroblastoma: Improved response rate using a multiagent regimen (OPEC) including sequential cisplatin and VM-26. J Clin Oncol 2:742-747, 1984
4. Rosen EM, Cassady JR, Frantz CN, et al: Stage IV-S: A favorable subset of children with metastatic neuroblastoma. Med Pediatr Oncol 13:194-198, 1985
5. Matthay KK, O'Leary MC, Ramsay NK, et al: Role of myeloablative therapy in improved outcome for high-risk neuroblastoma: Review of recent Children's Cancer Group results. Eur J Cancer 31A:572-575, 1995
6. Grahm-Pole JG, Casper J, Elfenbein G, et al: High-dose chemoradiotherapy supported by marrow infusions for advanced neuroblastoma: A Pediatric Oncology Group study. J Clin Oncol 9:152-158, 1991
7. Garaventa A, Rondelli R, Lanino E, et al: Myeloablative therapy and bone marrow rescue in advanced neuroblastoma. A report from the Italian Bone Marrow Transplant Registry. Italian Association of Pediatric Hematology-Oncology, BMT Group. Bone Marrow Transplant 18:125-130, 1996
8. Schulz G, Cheresh DA, Varki NM, et al: Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer Res 44:5914-5920, 1984
9. Cheung NK, Saarinen UM, Neely JE, et al: Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. Cancer Res 45:2642-2649, 1985
10. Cheung NK, Landmeier B, Neely J, et al: Complete tumor ablation with iodine 131-radiolabeled disialoganglioside GD2-specific monoclonal antibody against human neuroblastoma xenografted in nude mice. J Natl Cancer Inst 77:739-745, 1986
11. Houghton AN, Mintzer D, Cordon-Cardo C, et al: Mouse monoclonal IgG3 antibody detecting GD3 ganglioside. A phase I trial in patients with malignant melanoma. Proc Natl Acad Sci U S A 82:1242-1246, 1985
12. Cheung NK, Lazarus H, Miraldi FD, et al: Ganglioside GD2 specific monoclonal antibody 3F8: A phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol 5:1430-1440, 1987
13. Cheung NV, Lazarus H, Miraldi FD, et al: Reassessment of patient response to monoclonal antibody 3F8 (letter). J Clin Oncol 10:671-672, 1992
14. Huang CS, Uttenreuther M, Reisfeld RA, et al: Immunotherapy of GD2(+) tumors with a murine monoclonal antibody (MAB) 14G2a: A phase I study. Proc Am Soc Clin Oncol 11:364, 1992 (abstr)
15. Handgretinger R, Baader P, Dopfer R, et al: A phase I study of neuroblastoma with the antiganglioside GD2 antibody 14.G2a. Cancer Immunol Immunother 35:199-204, 1992
16. Murray JL, Cunningham JE, Brewer H, et al: Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. J Clin Oncol 12:184-193, 1994
17. Frost JD, Hank JA, Reaman GH, et al: A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: A report of the Children's Cancer Group. Cancer 80:317-333, 1997
18. Handgretinger R, Anderson K, Lang P, et al: A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma. Eur J Cancer 31A:261-267, 1995
19. Gillies SD, Lo KM, Wesolowski J: High-level expression of chimeric antibodies using adapted cDNA variable region cassettes. J Immunol Methods 125:191-202, 1989
20. Mujoo K, Kipps TJ, Yang HM, et al: Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18. Cancer Res 49:2857-2861, 1989
21. Barker E, Meuller BM, Handgretinger R, et al: Effect of a chimeric antiganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells. Cancer Res 51:144-149, 1991
22. Barker E, Reisfeld RA: A mechanism for neutrophil-mediated lysis of human neuroblastoma cells. Cancer Res 53:362-367, 1993
23. Mueller BM, Romerdahl CA, Gillies SD, et al: Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody. J Immunol 144:1382-1386, 1990
24. Yu AL, Gillies SD, Reisfeld RA: Phase I clinical trial of ch14.18 in patients with refractory neuroblastoma. Proc Am Soc Clin Oncol 10:318, 1991 (abstr)
25. Uttenreuther-Fischer MM, Huang CS, Yu AL: Pharmacokinetics of human-mouse chimeric anti-GD2 mAb ch14.18 in a phase I trial in neuroblastoma patients. Cancer Immunol Immunother 41:331-338, 1995
26. Van Wauwe JP, Goossens JG: The mitogenic activity of OKT3 and anti-Leu 4 monoclonal antibodies: A comparative study. Cell Immunol 77:23-29, 1983
27. Rodeck U, Herlyn M, Koprowski H: Interactions between growth factor receptors and corresponding monoclonal antibodies in human tumors. J Cell Biochem 35:315-320, 1987
28. Reisfeld RA: Monoclonal antibodies as targeting agents for chemotherapeutic drugs, in Albertini A (ed): Molecular Probes: Technology and Medical Applications. New York, NY, Raven, 1989, pp 173-180
29. Khazaeli MB: Quantitation of mouse monoclonal antibody and human antimouse antibody response in serum of patients. Hybridoma 8:231-239, 1989
30. Mosman T: Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assay. J Immunol Meth 65:55-63, 1983
31. Uttenreuther M, Huang CS, Tsui C, et al: Comparison of biological activity and pharmacokinetics between a mouse and a human-mouse anti-GD2 chimeric monoclonal antibody (MAB). Proc Am Assn Cancer Res 33:244, 1992 (abstr).
32. Huang CS, Uttenreuther-Fischer MM, Reisfeld RA, et al: Immune responses to a murine and a human-murine chimeric anti-GD2 antibody in cancer patients - Possible benefits from anti-Id Ab. Cancer, 1998 (submitted)
33. Saleh MN, Khazaeli MB, Wheeler RH, et al: Phase I trial of the murine monoclonal anti-GD2 antibody 14G2a in metastatic melanoma. Cancer Res 52:4342-4347, 1992
34. Saleh MN, Khazaeli MB, Wheeler RH, et al: Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma. Hum Antibodies Hybridomas 3:19-24, 1992
35. Svennerholm L, Bostrom K, Fredman P, et al: Gangliosides and allied glycosphingolipids in human peripheral nerve and spinal cord. Biochim Biophys Acta 1214:115-123, 1994
36. Slart R, Yu AL, Yaksh TL, et al: An animal model of pain produced by systemic administration of an immunotherapeutic antiganglioside antibody. Pain 69:119-125, 1997
37. 2 ganglioside antibody. Pain 69:145-151, 1997
38. Lawley TJ, Bielory L, Gascon P, et al: A study of human serum sickness. J Invest Dermatol 85:129S-132S, 1985
39. Korinek AM, Languille M, Bonnet F, et al: Effect of postoperative extradural morphine on ADH secretion. Br J Anaesth 57:407-411, 1985
40. Fanger MW, Shen L, Graziano RF, et al: Cytotoxicity mediated by human Fc-receptors for IgG. Immunol Today 10:92-99, 1989
41. Shawler DL, Bartholomew RM, Smith LM, et al: Human immune response to multiple injections of murine monoclonal IgG. J Immunol 135:1530-1535, 1985
42. Courtenay-Luck NS, Epenetos AA, Moore R, et al: Development of primary and secondary immune responses to mouse monoclonal antibodies used in the diagnosis and therapy of malignant neoplasms. Cancer Res 46:6489-6493, 1986
43. Brüggemann M, Winter G, Waldmann H, et al: The immunogenicity of chimeric antibodies. J Exp Med 170:2153-2157, 1989
44. Meredith RF, Khazaeli MB, Plott WE, et al: Phase I trial of iodine-131 chimeric B72.3 (human IgG4) in metastatic colorectal cancer. J Nucl Med 33:23-29, 1992
45. LoBuglio AF, Wheeler RH, Trang J, et al: Mouse/human chimeric monoclonal antibody in man: Kinetics and immune response. Proc Natl Acad Sci U S A 86:4220-4224, 1989
46. Yu AL, Reisfeld RA, Gillies SD: Immune response to monoclonal antibody therapy. Proc Am Assn Cancer Res 32:1566, 1991 (abstr)
47. Khazaeli MB, Saleh MN, Liu TP, et al: Pharmacokinetics and immune response of 131I-chimeric mouse/human B72.3 (human gamma 4) monoclonal antibody in humans. Cancer Res 51:5461-5466, 1991
48. Koprowski H, Herlyn D, Lubeck M, et al: Human anti-idiotype antibodies in cancer patients: Is the modulation of the immune response beneficial for the patient? Proc Natl Acad Sci U S A 81:216-219, 1984
49. Wettendorf M, Iliopoulos D, Schmoll E, et al: Specific detection of antibodies in cancer patients following immunotherapy with anti-idiotype. J Immunol Methods 116:105-115, 1989
50. Loibner H, Plot R, Rot A, et al: Immunoreactivity of a patient with colorectal cancer metastasis after immunisation with anti-idiotypes. Lancet 335:171, 1990
51. Yu AL, Uttenreuther MM, Kamps A, et al: Combined use of a human-mouse chimeric anti-GD2 (ch14.18) in the treatment of refractory neuroblastoma. Antibody Immunoconj Radiopharm 8:61, 1995 (abstr)
52. Yu AL, Batova A, Alvarado C, et al: Usefulness of a chimeric anti-GD2 (ch14.18) and GM-CSF for refractory neuroblastoma: A POG phase II study. Proc Am Soc Clin Oncol 16:1846, 1997 (abstr)